Free Trial

Gain Therapeutics (GANX) Competitors

$1.08
-0.04 (-3.57%)
(As of 07/24/2024 ET)

GANX vs. EVGN, PASG, HOOK, BYSI, CASI, VSTM, ASMB, LFVN, AFMD, and MIST

Should you be buying Gain Therapeutics stock or one of its competitors? The main competitors of Gain Therapeutics include Evogene (EVGN), Passage Bio (PASG), Hookipa Pharma (HOOK), BeyondSpring (BYSI), CASI Pharmaceuticals (CASI), Verastem (VSTM), Assembly Biosciences (ASMB), LifeVantage (LFVN), Affimed (AFMD), and Milestone Pharmaceuticals (MIST). These companies are all part of the "medical" sector.

Gain Therapeutics vs.

Gain Therapeutics (NASDAQ:GANX) and Evogene (NASDAQ:EVGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, community ranking, profitability, valuation and dividends.

Gain Therapeutics presently has a consensus target price of $8.25, suggesting a potential upside of 663.89%. Evogene has a consensus target price of $24.25, suggesting a potential upside of 4,020.65%. Given Evogene's higher possible upside, analysts clearly believe Evogene is more favorable than Gain Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gain Therapeutics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Evogene
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Gain Therapeutics has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Evogene has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500.

Gain Therapeutics has higher earnings, but lower revenue than Evogene. Evogene is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gain Therapeutics$50K389.88-$22.27M-$1.50-0.72
Evogene$5.64M4.30-$23.88M-$0.46-1.28

Gain Therapeutics has a net margin of 0.00% compared to Evogene's net margin of -233.66%. Evogene's return on equity of -70.96% beat Gain Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gain TherapeuticsN/A -213.34% -129.04%
Evogene -233.66%-70.96%-41.10%

Evogene received 193 more outperform votes than Gain Therapeutics when rated by MarketBeat users. However, 65.00% of users gave Gain Therapeutics an outperform vote while only 58.24% of users gave Evogene an outperform vote.

CompanyUnderperformOutperform
Gain TherapeuticsOutperform Votes
26
65.00%
Underperform Votes
14
35.00%
EvogeneOutperform Votes
219
58.24%
Underperform Votes
157
41.76%

In the previous week, Evogene had 5 more articles in the media than Gain Therapeutics. MarketBeat recorded 6 mentions for Evogene and 1 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 0.00 beat Evogene's score of -0.29 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Gain Therapeutics Neutral
Evogene Neutral

12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 10.4% of Evogene shares are owned by institutional investors. 11.7% of Gain Therapeutics shares are owned by insiders. Comparatively, 7.4% of Evogene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Gain Therapeutics beats Evogene on 9 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GANX vs. The Competition

MetricGain TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$19.49M$7.48B$5.39B$8.22B
Dividend YieldN/A2.84%2.79%3.95%
P/E Ratio-0.7214.03143.5617.01
Price / Sales389.88300.412,253.7485.29
Price / CashN/A32.2334.9234.34
Price / Book1.115.774.894.40
Net Income-$22.27M$146.99M$110.52M$216.22M
7 Day Performance-14.96%-2.15%-1.14%-2.35%
1 Month Performance-16.28%8.16%8.68%5.57%
1 Year Performance-74.41%-0.77%8.29%1.65%

Gain Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EVGN
Evogene
1.5028 of 5 stars
1.50 / 5 stars
$0.60
+1.7%
$3.62
+502.9%
-94.7%$24.51M$5.64M-1.30142Analyst Forecast
Stock Split
News Coverage
Gap Up
PASG
Passage Bio
1.8812 of 5 stars
1.88 / 5 stars
$0.90
+1.1%
$9.00
+900.1%
-11.9%$55.47MN/A-0.5958News Coverage
HOOK
Hookipa Pharma
2.354 of 5 stars
2.35 / 5 stars
$6.42
+1.1%
$50.00
+678.8%
-28.7%$63.56M$20.13M-1.2856Positive News
Gap Down
BYSI
BeyondSpring
0 of 5 stars
0.00 / 5 stars
$2.20
-4.8%
N/A+72.1%$85.87M$1.75M0.0036Upcoming Earnings
Gap Down
CASI
CASI Pharmaceuticals
2.3654 of 5 stars
2.37 / 5 stars
$6.35
-3.2%
$6.00
-5.5%
+169.7%$85.09M$33.88M-2.79180Gap Down
VSTM
Verastem
3.3751 of 5 stars
3.38 / 5 stars
$3.32
+0.9%
$22.21
+569.1%
-69.4%$84.10M$2.60M-0.7550Analyst Downgrade
News Coverage
Gap Down
ASMB
Assembly Biosciences
0.6892 of 5 stars
0.69 / 5 stars
$15.13
+0.9%
N/A+12.7%$83.37M$7.16M0.0065News Coverage
LFVN
LifeVantage
2.8628 of 5 stars
2.86 / 5 stars
$6.61
+1.1%
N/A+40.3%$83.06M$213.40M23.61248Positive News
AFMD
Affimed
3.7633 of 5 stars
3.76 / 5 stars
$5.15
-5.3%
$41.67
+709.1%
-13.2%$82.84M$8.95M0.00200News Coverage
Positive News
MIST
Milestone Pharmaceuticals
1.7935 of 5 stars
1.79 / 5 stars
$1.48
-4.5%
$13.00
+778.4%
-52.3%$82.57M$1M-1.1847

Related Companies and Tools

This page (NASDAQ:GANX) was last updated on 7/25/2024 by MarketBeat.com Staff

From Our Partners